Cell Source, Inc. CLCS
We take great care to ensure that the data presented and summarized in this overview for Cell Source, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLCS
Top Purchases
Top Sells
About CLCS
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Insider Transactions at CLCS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
19,440
+0.44%
|
$0
$0.75 P/Share
|
|
Jun 30
2021
|
Dennis M Brown Director |
BUY
Other acquisition or disposition
|
Direct |
2,976
+2.52%
|
$0
$0.75 P/Share
|
|
Jun 30
2021
|
Darlene Soave Director |
BUY
Other acquisition or disposition
|
Direct |
59,507
+25.44%
|
$0
$0.75 P/Share
|
|
Jun 30
2021
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
4,860
+0.43%
|
$0
$0.75 P/Share
|
|
Dec 29
2020
|
Dennis M Brown Director |
BUY
Other acquisition or disposition
|
Direct |
3,025
+2.63%
|
$0
$0.75 P/Share
|
|
Dec 29
2020
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
19,672
+0.44%
|
$0
$0.75 P/Share
|
|
Dec 29
2020
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
4,941
+0.44%
|
$0
$0.75 P/Share
|
|
Jun 30
2020
|
Dennis M Brown Director |
BUY
Other acquisition or disposition
|
Direct |
2,992
+2.67%
|
$0
$0.75 P/Share
|
|
Jun 30
2020
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
19,547
+0.44%
|
$0
$0.75 P/Share
|
|
Jun 30
2020
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
4,887
+0.44%
|
$0
$0.75 P/Share
|
|
Dec 31
2019
|
Dennis M Brown Director |
BUY
Other acquisition or disposition
|
Direct |
5,934
+5.3%
|
$0
$0.75 P/Share
|
|
Dec 31
2019
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
25,675
+0.58%
|
$0
$0.75 P/Share
|
|
Dec 31
2019
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
6,420
+0.58%
|
$0
$0.75 P/Share
|
|
Jun 26
2019
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
5,356
+0.12%
|
$0
$0.75 P/Share
|
|
Jun 26
2019
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
1,339
+0.12%
|
$0
$0.75 P/Share
|
|
Dec 31
2018
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
5,444
+0.12%
|
$0
$0.75 P/Share
|
|
Dec 31
2018
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
1,361
+0.12%
|
$0
$0.75 P/Share
|
|
Aug 21
2018
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
6,672
+0.15%
|
$0
$0.75 P/Share
|
|
Aug 21
2018
|
David Zolty Director |
BUY
Other acquisition or disposition
|
Indirect |
1,668
+0.15%
|
$0
$0.75 P/Share
|
|
Dec 04
2017
|
Benzion Abraham Friedman Director |
BUY
Other acquisition or disposition
|
Indirect |
5,400
+0.12%
|
$0
$0.75 P/Share
|